Healio AI Partners with Holland Foundation for Sight Restoration to Enhance Ocular Disease Care

Healio AI, a HIPAA-compliant artificial intelligence platform designed to support healthcare professionals with evidence-based insights, has announced a strategic partnership with The Holland Foundation for Sight Restoration (HFSR). This collaboration aims to integrate HFSR’s specialized educational content, including the fundamentals of the Cincinnati Protocol for stem cell transplantation in patients with severe ocular surface disease, into Healio AI’s knowledge base.

Strengthening Access to Trusted Medical Insights

The partnership underscores Healio AI’s commitment to providing physicians with up-to-date, verified information to improve patient care. According to Stephen S. Lane, MD, chair of the board of directors for HFSR, the collaboration addresses a critical need for accessible, authoritative resources in ophthalmology. “Staying current with the most up-to-date medical opinions and treatment strategies is at the essence of what it means to be a physician,” Lane said. “This partnership leverages Healio AI’s trusted corpus of knowledge to eliminate barriers to physicians accessing comprehensive content whenever and wherever they need it.”

Joan-Marie Stiglich, ELS, Chief AI Officer at Healio, emphasized the significance of the collaboration. “Bringing a one-of-a-kind source to a one-of-a-kind platform is a powerful step forward for trusted clinical AI,” she stated. “In a time when trust matters more than ever, this partnership strengthens our commitment to delivering authoritative, reliable answers backed by the industry’s most respected content.”

About the Cincinnati Protocol and HFSR

The Cincinnati Protocol, developed by HFSR founder Edward J. Holland, MD, is a standardized approach to stem cell transplantation for severe ocular surface disease. By integrating this protocol into Healio AI, healthcare professionals will gain deeper insights into advanced treatment strategies for complex eye conditions. HFSR, a 501(c)(3) nonprofit organization, has long been dedicated to advancing care for patients with ocular surface disorders through research, education, and innovation.

Healio AI, launched in November 2025, aggregates data from PubMed, clinical trials, FDA updates, and peer-reviewed journals to deliver real-time, evidence-based guidance. The platform’s expansion to include HFSR content reflects its mission to support point-of-care decision-making with actionable, verified information.

Implications for Healthcare Providers

The integration of HFSR’s educational materials into Healio AI is expected to enhance clinical workflows by providing physicians with streamlined access to specialized knowledge. This partnership aligns with broader trends in healthcare, where AI-driven tools are increasingly used to bridge gaps in medical education and treatment accessibility.

As Healio AI continues to evolve, its focus on collaboration with niche medical organizations like HFSR highlights the growing importance of tailored, expert-driven AI solutions in modern medicine.

Key Takeaways

• Healio AI has partnered with The Holland Foundation for Sight Restoration to integrate the Cincinnati Protocol into its knowledge base.
• The collaboration aims to improve access to evidence-based insights for physicians treating ocular surface disease.
• Healio AI’s platform aggregates data from peer-reviewed journals, clinical trials, and FDA sources to support point-of-care decision-making.